Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

@article{Poynard2014StagingCH,
  title={Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).},
  author={Thierry Poynard and Julien Vergniol and Yen Ngo and Juliette Foucher and Vincent Thibault and M. J. Munteanu and Wassil Merrouche and Pascal Lebray and Marika Rudler and Olivier Deckmyn and Hugo Perazzo and Dominique Thabut and Vlad Ratziu and Victor de Ledinghen},
  journal={Journal of hepatology},
  year={2014},
  volume={61 5},
  pages={994-1003}
}
BACKGROUND & AIMS The first aim was to extend the validation of FibroTest® (FT) and transient elastography (TE) as markers of occurrence of cirrhosis without complications (F4.1), oesophageal varices (F4.2), and severe complications (F4.3) in patients with chronic hepatitis B (CHB). The second aim was to validate a previous definition of an inactive carrier based on normal FT and ActiTest® (normal-FT-AT). The third aim was to assess the long-term dynamics of fibrosis in patients with sustained… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Hepatitis B: are non-invasive markers of liver fibrosis reliable?

Liver international : official journal of the International Association for the Study of the Liver • 2014
View 4 Excerpts
Highly Influenced

Management of hepatitis B: our practice and how it relates to the guidelines.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…